Work

Phase I Study of Tagraxofusp with or without Chemotherapy in Pediatric Patients with Relapsed or Refractory CD123-Expressing Hematologic Malignancies: A Therapeutic Advances in Childhood Leukemia and Lymphoma (TACL) Consortium Trial

Year: 2022

Type: article

Source: Blood

DOI: 10.1182/blood-2022-163503

Authors: Adam J. Lamble, Yueh-Yun Chi, Bill H. Chang, Anupam Verma, Kelly E Faulk, Alexandra McLean Stevens, Lauren Pommert, Sarah Tucker, Benjamin Brookhart, Nirali N. Shah, Christopher L. Brooks, Tariq I. Mughal, Alan S. Wayne, Soheil Meshinchi, Todd M. Cooper

Institutions: Seattle Children's Hospital, Children's Hospital Los Angeles, Oregon Health & Science University, National Institutes of Health, Children's Hospital Colorado, Baylor College of Medicine, Cincinnati Children's Hospital Medical Center, University of Cincinnati, National Cancer Institute, Stemline Therapeutics (United States), Fred Hutch Cancer Center

Language: English

Topic: Acute Lymphoblastic Leukemia research

Subfield: Public Health, Environmental and Occupational Health

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W4310117599

FWCI: 0.597

Cites:

Cited by: 3

Related to: 10